Problem

Clinical-trial biometrics and regulatory submission work remains slow, fragmented, and labor-intensive. Astraea says the process can take about nine months with teams of five to ten people coordinating asynchronously across Word documents, Excel specifications, SAS programs, manual handoffs, version-control problems, and repeated QC cycles. The highest-value use case is complex Phase II and III work—initially oncology and rare-disease studies—where analysis complexity is high and every month saved has meaningful economic value. Astraea claims its automation can make reporting cycles 30–50% faster and remove 12–30 days from a typical 40–60-business-day post-lock CSR timeline.

Product / Service

Astraea is sponsor-run clinical-trial automation software deployed inside the customer’s own environment, so the company says clinical data never leaves the customer’s infrastructure and Astraea does not see or store it. Its multi-agent AI takes inputs such as protocols, CRFs, statistical analysis plans, and raw study data, then automates data normalization, CDISC mapping, SDTM and ADaM datasets, TFLs, Define-XML, QC, evidence synthesis, and FDA submission documents. The platform is designed as an auditable execution layer rather than a replacement for biostatisticians, programmers, or medical writers: human reviewers remain responsible for approval, validation, and regulatory decisions while the system logs lineage and workflow steps.

Market

Astraea competes in enterprise clinical-trial automation, clinical biometrics, clinical data standards, and regulatory-submission software. The incumbent alternative set includes broad clinical platforms such as Medidata and Veeva, Biovia, SAS-based CRO services, and specialized tools such as Pinnacle 21 for CDISC validation. Astraea’s differentiation is its attempt to unify the post-protocol-to-submission workflow in one standards-native, agentic-AI system rather than offering only a point validation tool or outsourced service.

The company is an active Y Combinator Spring 2026 startup with a two-person team, and its website claims the product is trusted across more than ten global pharmaceutical and biotech sponsors, spanning first-in-human programs through top-three global pipelines. That indicates early commercial traction rather than a purely pre-revenue concept, although the available materials do not disclose revenue, contract values, or whether every sponsor relationship is paid. The product is marketed through demos and enterprise partnerships, consistent with a high-touch enterprise software sales model.